非小细胞肺癌治疗进展
Progress in Treatment of Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2022.126851, PDF,   
作者: 汪 檬, 常小红：延安大学附属医院呼吸内科，陕西 延安
关键词: 非小细胞肺癌；联合治疗；治疗进展；Non-Small Cell Lung Cancer； Combination Therapy； Treatment Progress
摘要: 非小细胞肺癌(NSCLC, Non-Small Cell Lung Cancer)是呼吸系统最常见的一种恶性肿瘤，其预后及中位生存期均比较差，目前早期治疗主要是以手术治疗为主，中晚期则是以靶向化疗为主，目前非小细胞肺癌的治疗方法主要包括：化疗药物治疗、中医治疗、分子靶向治疗、手术治疗等方式。其中手术治疗作为早期非小细胞肺癌的主要治疗手段。现就非小细胞肺癌的治疗方法回顾如下。
Abstract: Non-small Cell Lung Cancer (NSCLC) is the most common type of respiratory nausea tumor, with poor prognosis and median survival. Currently, surgery is the main treatment in the early stage, and targeted chemotherapy is the main treatment in the late stage. At present, the treatment methods of NSCLC mainly include: chemotherapy drug therapy, traditional Chinese medicine ther-apy, molecular targeted therapy, surgical treatment, and so on. Surgical treatment is the main treatment for early NSCLC. The treatment of NSCLC is reviewed as follows.
文章引用：汪檬, 常小红. 非小细胞肺癌治疗进展[J]. 临床医学进展, 2022, 12(6): 5882-5886. https://doi.org/10.12677/ACM.2022.126851

参考文献

[1] 杨森, 谢颂平, 黄杰. 可手术切除的局部进展期非小细胞肺癌患者新辅助治疗研究进展[J]. 实用心脑肺血管病杂志, 2022, 30(3): 131-136.
[2] 汪程, 胡剑鹏, 张骥, 徐伟, 陈师. 胸腔镜微创术与传统开胸术治疗非小细胞肺癌的对比分析[J]. 中国卫生标准管理, 2021, 12(18): 34-37.
[3] 丁国强, 白舒, 刘鸿运, 张大勇, 袁井贺. 单孔与三孔胸腔镜在早期肺癌手术治疗中的对比观察及对恢复时间的影响[J]. 航空航天医学杂志, 2019, 30(8): 948-949.
[4] 马长辉, 周悦, 刘锦源. 单孔胸腔镜手术治疗早期肺癌临床研究[J]. 中国临床研究, 2020, 33(1): 59-61+65. [Google Scholar] [CrossRef] 
[5] 李德刚. 胸腔镜肺癌手术与传统开胸手术在治疗老年非小细胞肺癌的临床指标对比[J]. 系统医学, 2020, 5(4): 73-75+84. [Google Scholar] [CrossRef] 
[6] NSCLC Meta-Analysis Collaborative Group (2014) Preoperative Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Participant Data. The Lancet, 383, 1561-1571. [Google Scholar] [CrossRef] 
[7] 邹灵俊, 陈洪波, 郭晓康, 孙健, 张燕, 张德贤, 郭洪波. 非小细胞肺癌新辅助化疗联合手术预后影响因素分析[J]. 中华肿瘤防治杂志, 2022, 29(3): 179-185.
[8] 沈国刚, 李志杰, 陈羽彪. 探究术前新辅助化疗联合外科手术治疗非小细胞肺癌的临床效果[J]. 中国实用医药, 2020, 15(16): 45-47. [Google Scholar] [CrossRef] 
[9] 丁江华, 龚升平. 多西紫杉醇及参一胶囊节拍疗法治疗老年进展期非小细胞肺癌[J]. 临床误诊误治, 2010, 23(1): 59-61.
[10] Nagasaka, M. and Gadg-eel, S.M. (2018) Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. Expert Re-view of Anticancer Therapy, 18, 63-70. [Google Scholar] [CrossRef] [PubMed]
[11] Yoneda, K., Imanishi, N., Ichiki, Y. and Tanaka, F. (2019) Treatment of Non-Small Cell Lung Cancer with EGFR-Mutations. Journal of UOEH, 41, 153-163. [Google Scholar] [CrossRef] [PubMed]
[12] Yang, J.C.-H., Ahn, M.-J., Kim, D.-W., Ramalin-gam, S.S., Sequist, L.V., Su, W.-C., et al. (2017) Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 35, 1288-1296. [Google Scholar] [CrossRef] 
[13] Lazzari, C., Gregorc, V., Karachaliou, N., Rosell, R. and Santarpia, M. (2020) Mechanisms of Resistance to Osimertinib. The Journal of Thoracic Disease, 12, 2851-2858. [Google Scholar] [CrossRef] [PubMed]
[14] Xie, L., Nagpal, S., Wakelee, H.A., Li, G., Soltys, S.G. and Neal, J.W. (2019) Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. Oncologist, 24, 836-843. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, R., Manochakian, R., James, L., Azzouqa, A.G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K. and Lou, Y. (2020) Emerging Therapeutic Agents for Advanced Non-Small Cell Lung Cancer. Journal of Hematology & Oncology, 13, 58. [Google Scholar] [CrossRef] [PubMed]
[16] Rijavec, E., Indini, A., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F. and Grossi, F. (2021s) Nivolumab plus Ipilimumab for the First-Line Treatment of Metastatic NSCLC. Expert Review of Anticancer Therapy, 21, 705-713. [Google Scholar] [CrossRef] [PubMed]
[17] 宋丽君, 马雪娇, 郑佳彬, 王学谦, 张英, 刘杰, 侯炜, 林丽珠, 蒋益兰, 解英, 李平, 王沈玉, 张洪亮, 舒琦瑾, 林洪生. 中医综合方案联合化疗治疗IV期非小细胞肺癌的多中心随机对照研究[J]. 北京中医药, 2022, 41(1): 2-6. [Google Scholar] [CrossRef] 
[18] Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Personal-ized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. [Google Scholar] [CrossRef] [PubMed]
[20] Dal Maso, A., Lorenzi, M., Ferro, A., et al. (2021) Real-World Data on Treatment Outcomes in EGFR-Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology, 17, 2513-2527. [Google Scholar] [CrossRef] [PubMed]

为你推荐